Moxifloxacin for Bacterial Conjunctivitis

Clinical Efficacy

Moxifloxacin demonstrates superior gram-positive coverage compared to earlier generation fluoroquinolones in head-to-head studies, according to the American Academy of Ophthalmology 1, 2

Methicillin resistance occurs in 42% of staphylococcal isolates with high concurrent fluoroquinolone resistance, as reported by the Infectious Diseases Society of America 4, 2
For suspected MRSA conjunctivitis, the American Academy of Ophthalmology recommends switching to compounded topical vancomycin 1, 4, 2
A 20-year San Francisco study showed increasing overall resistance to moxifloxacin from 1996 to 2015, according to the Centers for Disease Control and Prevention 3, 1, 2
In southern India, Pseudomonas aeruginosa resistance to moxifloxacin increased sharply from 19% in 2007 to 52% in 2009, as reported by the World Health Organization 3, 2
Risk factors for fluoroquinolone resistance include recent fluoroquinolone use, recent hospitalization, advanced age, and recent ocular surgery, according to the American Academy of Ophthalmology 1, 4, 2

Systemic antibiotic therapy is mandatory—topical treatment alone is insufficient, as recommended by the Centers for Disease Control and Prevention 5, 4, 2
Add topical moxifloxacin only as adjunctive therapy if corneal involvement is present, according to the American Academy of Ophthalmology 5
Patients require daily follow-up until resolution, as recommended by the Infectious Diseases Society of America 5, 1

Systemic therapy is required, particularly in infants who may have infection at other sites (nasopharynx, genital tract, lungs), according to the American Academy of Pediatrics 5, 1
Topical therapy provides no additional benefit beyond systemic treatment, as reported by the Centers for Disease Control and Prevention 5

Obtain conjunctival cultures and Gram staining before initiating therapy, as recommended by the American Academy of Ophthalmology 5
Consider compounded topical vancomycin if MRSA is suspected based on microbiology results, according to the Infectious Diseases Society of America 5

Advise patients to return in 3-4 days if no improvement is noted, as recommended by the American Academy of Ophthalmology 5, 1
If no improvement after 7 days, reevaluate the diagnosis and consider alternative pathogens or resistance, according to the Infectious Diseases Society of America 2
For treatment failures, obtain cultures and consider switching to vancomycin for MRSA or colistin 0.19% for resistant Pseudomonas, as recommended by the American Academy of Ophthalmology 4, 2

While moxifloxacin is widely used off-label for bacterial keratitis, it is not FDA-approved for this indication, as reported by the American Academy of Ophthalmology 1
Besifloxacin 0.6% may offer better coverage against ciprofloxacin- and methicillin-resistant staphylococci than moxifloxacin, according to the Infectious Diseases Society of America 1, 4